Literature DB >> 27366211

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Suzanne Russo1, M Wasif Saif2.   

Abstract

Entities:  

Year:  2016        PMID： 27366211      PMCID： PMC4913343          DOI： 10.1177/1756283X16646524

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


× No keyword cloud information.
  76 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.

Authors:  Jae-Lyun Lee; Song Cheol Kim; Ji-Hoon Kim; Sang Soo Lee; Tae-Won Kim; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Myung-Hwan Kim; Jong Hoon Kim; Jin-Hong Park; Sang Hyun Shin; Duck Jong Han
Journal:  Surgery       Date:  2012-06-06       Impact factor: 3.982

3.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.

Authors:  Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson
Journal:  J Surg Oncol       Date:  2010-06-01       Impact factor: 3.454

4.  Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

Authors:  R R White; H I Hurwitz; M A Morse; C Lee; M S Anscher; E K Paulson; M R Gottfried; J Baillie; M S Branch; P S Jowell; K M McGrath; B M Clary; T N Pappas; D S Tyler
Journal:  Ann Surg Oncol       Date:  2001-12       Impact factor: 5.344

5.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

6.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

7.  NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.

Authors:  Klaus Sahora; Irene Kuehrer; Martin Schindl; Claus Koelblinger; Peter Goetzinger; Michael Gnant
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

8.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

9.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Authors:  William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

10.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860
View more
  4 in total

1.  Completion of adjuvant therapy in patients with resected pancreatic cancer.

Authors:  Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming
Journal:  HPB (Oxford)       Date:  2019-09-25       Impact factor: 3.647

2.  Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.

Authors:  Yoo Jin Choi; Yoonhyeong Byun; Jae Seung Kang; Hyeong Seok Kim; Youngmin Han; Hongbeom Kim; Wooil Kwon; Do-Youn Oh; Woo Hyun Paik; Sang Hyub Lee; Ji Kon Ryu; Yong-Tae Kim; Kyungbun Lee; Haeryoung Kim; Eui Kyu Chie; Jin-Young Jang
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

3.  High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study.

Authors:  Malte Weinrich; Johanna Bochow; Anna-Lisa Kutsch; Guido Alsfasser; Christel Weiss; Ernst Klar; Bettina M Rau
Journal:  Ann Med Surg (Lond)       Date:  2018-06-27

4.  Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.

Authors:  Soomin Ahn; Jong-Chan Lee; Jaihwan Kim; Young Hoon Kim; Yoo-Seok Yoon; Ho-Seong Han; Haeryoung Kim; Jin-Hyeok Hwang
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.